144 related articles for article (PubMed ID: 36131010)
1. Allopurinol and prostate cancer survival in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):73-80. PubMed ID: 36131010
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):373-378. PubMed ID: 29273728
[TBL] [Abstract][Full Text] [Related]
5. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of prostate cancer screening among men using antidiabetic medication.
Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
Joentausta RM; Rannikko A; Murtola TJ
Prostate; 2019 May; 79(6):583-591. PubMed ID: 30652328
[TBL] [Abstract][Full Text] [Related]
9. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
[TBL] [Abstract][Full Text] [Related]
11. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
Salminen JK; Mehtola A; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
Br J Cancer; 2022 Sep; 127(4):704-711. PubMed ID: 35505251
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
[TBL] [Abstract][Full Text] [Related]
13. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.
Booth N; Rissanen P; Tammela TLJ; Taari K; Talala K; Auvinen A
Eur J Cancer; 2018 Apr; 93():108-118. PubMed ID: 29501976
[TBL] [Abstract][Full Text] [Related]
14. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PT; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
Scand J Urol; 2016 Dec; 50(6):413-419. PubMed ID: 27628763
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
Kinnunen PTT; Murtola TJ; Talala K; Taari K; Tammela TLJ; Auvinen A
BMC Cancer; 2017 Aug; 17(1):585. PubMed ID: 28851310
[TBL] [Abstract][Full Text] [Related]
16. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Vihervuori VJ; Lahtela J; Talala K; Taari K; Tammela TL; Auvinen A
Br J Cancer; 2018 May; 118(9):1248-1254. PubMed ID: 29563633
[TBL] [Abstract][Full Text] [Related]
17. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
18. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
[TBL] [Abstract][Full Text] [Related]
19. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Salminen JK; Kuoppamäki V; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
Int J Cancer; 2021 Jul; 149(2):307-315. PubMed ID: 33634851
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study.
Santala EE; Rannikko A; Murtola TJ
Int J Cancer; 2019 Feb; 144(3):440-447. PubMed ID: 30110124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]